Farley did not elaborate on his views, but he is hardly the only Fortune 500 CEO who believes AI could spell trouble for ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

In early 2024, Moderna’s compensation committee set Bancel’s performance-based bonus maximum at 150% of his salary, which would have come out to $2.45 million if he met all of his goals.

Nov 5 (Reuters) - Vaccine maker Moderna's (MRNA.O) chief executive officer Stephane Bancel will vacate his role as the company's chief commercial officer, Bloomberg News reported on Tuesday citing ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter. He will remain chief executive officer of the biotech company.

Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, why the company is slashing its full-year sales guidance, state of the company's Covid vaccines ...

Assuming a typical eight-hour workday, that means Bancel expects his staff to ask OpenAI’s chatbots questions at least two, maybe three times every hour–an AI interaction rate that could ...